Zeller J A, Lenz A, Eschenfelder C C, Zunker P, Deuschl G
Department of Neurology, Christian-Albrechts-University, Kiel, Germany.
Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1519-23. doi: 10.1161/01.ATV.0000167524.69092.16. Epub 2005 Apr 21.
Acute coronary syndromes and ischemic cerebral stroke share similarities regarding elevated platelet activation. In coronary syndromes, the importance of inflammation with platelet-leukocyte interaction has been demonstrated. Recent infection is an established risk factor for ischemic stroke; the role of platelet-leukocyte interaction in these patients had not been investigated.
Using a flow cytometric assay we investigated 58 stroke patients, 21 with and 37 without infection 1 week before acute cerebral ischemia, and compared them to 58 controls with regard to platelet-leukocyte aggregation and platelet activation on admission and on day 7. Patients with previous infection were significantly up-regulated with regard to platelet activation and platelet-leukocyte aggregation compared with patients without infection. On day 7, these increases in the postinfective group had drawn level with the lower values of the other patients. As reported previously, recent infection was associated with a more severe postischemic deficit.
These results suggest an important role of intercellular platelet-leukocyte interaction in the pathophysiology of acute cerebral ischemia which may also contribute to the increased incidence and clinical severity of ischemic stroke following infection. This may lead to therapeutic considerations of blocking intercellular adhesion molecules like P-selectin or the P-selectin glycoprotein ligand.
急性冠脉综合征和缺血性脑卒在血小板活化升高方面存在相似之处。在冠脉综合征中,炎症与血小板-白细胞相互作用的重要性已得到证实。近期感染是缺血性卒中公认的危险因素;尚未对这些患者中血小板-白细胞相互作用的作用进行研究。
我们采用流式细胞术检测了58例卒中患者,其中21例在急性脑缺血前1周有感染,37例无感染,并将他们在入院时和第7天时的血小板-白细胞聚集及血小板活化情况与58例对照者进行比较。与未感染患者相比,既往有感染的患者在血小板活化和血小板-白细胞聚集方面显著上调。在第7天,感染后组的这些升高已与其他患者的较低值持平。如先前报道,近期感染与更严重的缺血后缺损相关。
这些结果提示细胞间血小板-白细胞相互作用在急性脑缺血的病理生理学中起重要作用,这也可能导致感染后缺血性卒中的发病率和临床严重程度增加。这可能会引发对阻断细胞间黏附分子如P-选择素或P-选择素糖蛋白配体进行治疗的考虑。